PSAT1

Across TCGA pan-cancer cohorts, PSAT1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSAT1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PSAT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSAT1 expression acts as an unfavorable survival marker.

CCRCC, GBM, and LUAD are the cancer types where PSAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.509	0.926	.012	14	view →
GBM	OS	Tertile	All	0.327	0.686	.006	9	view →
LUAD	DFS	Tertile	All	0.382	0.828	.004	6	view →
PDAC	OS	Tertile	IV	0.443	0.973	.024	6	view →
UCEC	DFS	Quartile	All	0.705	0.889	.047	2	view →
HNSC	OS	Median	All	0.806	0.900	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSAT1–CCRCC (OS)

Open the CCRCC breakdown →